Pain Reduction of an Oral Gabapentin and Median Nerve Neural Mobilization Combined Treatment Compared to Only Oral Gabapentin in Subjects Who Suffer Carpal Tunnel Syndrome
Status: Completed
Location: See location...
Intervention Type: Combination product, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
In the present investigation the pain reduction effects of a physiotherapy technique combined with pharmaceutical gabapentin treatment will be compared to those produced by gabapentin (only) treatment, in subjects who suffer the signs and symptoms of carpal tunnel syndrome.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 70
Healthy Volunteers: t
View:
• Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
• Full understanding of written and spoken Spanish (language).
• Participants must freely consent to participate.
• The presence of positive Phalen and Tinel signs.
• The presence of carpal tunnel syndrome signs and symptoms
Locations
Other Locations
Bolivarian Republic of Venezuela
Ciudad Hospitalaria Enrique Tejera
Valencia
Time Frame
Start Date: 2025-02-19
Completion Date: 2025-03-25
Participants
Target number of participants: 72
Treatments
Experimental: Median nerve neural mobilization and oral gabapentin
Median nerve neural mobilization, non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induce median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 2 weeks. This arm will also receive a Gabapentin Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 600 mg per day, subdivided in 2 intakes of 300 mg each 12 hours during a time lapse of 2 weeks.
Active_comparator: Gabapentin
Gabapentin Oral capsule pharmaceutical treatment. Participants will be treated with a maximum of 600 mg per day, subdivided in 2 intakes of 300 mg each 12 hours during a time lapse of 2 weeks.
Related Therapeutic Areas
Sponsors
Leads: Universidad Europea de Madrid